Accession Number : ADA190902

Title :   Development of Microcomputer Methods for Analysis and Simulation of Clinical Pharmacokinetic Data Relevant to New Drug Development.

Descriptive Note : Annual rept. 1 Jan 84-30 Apr 85,

Corporate Author : DUKE UNIV DURHAM NC DIV OF CLINICAL PHARMACOLOGY

Personal Author(s) : Bjornsson, Thorir D ; Wagoner, Robert

PDF Url : ADA190902

Report Date : 29 Apr 1985

Pagination or Media Count : 9

Abstract : The research proposed under this contract is a feasibility study in the development of applications of new microcomputer graphics technology to the continuing development of comprehensive programs for analysis, interpretation, and simulation of pharmacokinetic data, dose-response kinetic data, and other data relevant to new drug development, for use with the Tektronix 4052 Microcomputer Graphics System. The combination of such modern analytical and illustrative methods in clinical pharmacology, based on new high-speed microcomputers and associated graphics, are thought to greatly reduce both cost and time involved in the overall process of clinical evaluation of new drugs in the U.S. Army Drug Development Program. The work performed includes the following: Continuing developments of the programs for the analysis and simulation of non-linear kinetic data. Development of a translation program for the conversion of various sets of pharmacokinetic parameters into a uniform set. Keywords: Clinical pharmacokinetics, Dose-response relations, Pharmacokinetic simulation, Non-Parametric statistics, Mefloquine, Microcomputer graphics, Pharmacology.

Descriptors :   *CLINICAL MEDICINE, *PHARMACOKINETICS, *MEDICAL COMPUTER APPLICATIONS, *BIOMEDICAL INFORMATION SYSTEMS, COSTS, DOSAGE, DRUGS, EXPERIMENTAL DATA, FEASIBILITY STUDIES, GRAPHICS, METHODOLOGY, MICROCOMPUTERS, PHARMACOLOGY, RESPONSE(BIOLOGY), SIMULATION, STATISTICS, TEST AND EVALUATION, COMPUTER GRAPHICS, COMPUTER PROGRAMS, MILITARY MEDICINE, ARMY RESEARCH

Subject Categories : Pharmacology
      Medicine and Medical Research

Distribution Statement : APPROVED FOR PUBLIC RELEASE